SCHEMBL21995507

SCHEMBL21995507

CC1(C)CC(=O)NC(=O)N1c1ccc(Oc2ccccc2)cc1

nearest known ligand 0.48

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MMP2 P08253 6/20 0.48
MMP9 P14780 6/20 0.48
MMP13 P45452 5/20 0.48
MMP3 P08254 4/20 0.48
MGLL Q99685 2/20 0.44
NTRK1 P04629 2/20 0.43
IGF1R P08069 2/20 0.43
FGFR1 P11362 2/20 0.43
NTRK2 Q16620 2/20 0.43
MMP8 P22894 1/20 0.43
NTRK3 Q16288 1/20 0.43
NPC1 O15118 1/20 0.43
LTA4H P09960 1/20 0.42
LMNA P02545 1/20 0.41
PLCG1 P19174 1/20 0.40
MAOA P21397 1/20 0.39
MAOB P27338 1/20 0.39
AKR1B1 P15121 1/20 0.38
HPGD P15428 1/20 0.38
FAAH O00519 1/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL24155474 0.70 CRBN (0.73) MMP2MMP9MMP13MMP3MGLL
SCHEMBL6799176 0.70 MAPT (0.68) MMP2MMP9MMP13MMP3MGLL
SCHEMBL21995551 0.70 HPGD (0.47) MMP2MMP9MMP13MMP3MGLL
SCHEMBL22904555 0.70 LTA4H (0.55) MMP2MMP9MMP13MMP3MGLL
SCHEMBL9795636 0.69 MMP2 (0.46) MMP2MMP9MMP13MMP3MGLL
SCHEMBL9729935 0.68 MMP13 (0.66) MMP2MMP9MMP13MMP3MGLL
SCHEMBL4283528 0.67 DDB1 (0.46) MMP13NPC1
SCHEMBL24155934 0.67 MMP2 (0.50) MMP2MMP9MMP13MMP3MGLL
SCHEMBL1191959 0.67 AR (0.55) MMP2MMP9MMP13MMP3MGLL
SCHEMBL11830082 0.66 MMP2 (0.51) MMP2MMP9MMP13MMP3MMP8

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20250304558-A1 HETEROCYCLIC COMPOUNDS FOR THE TREATMENT OF EPILEPSY OTSUKA PHARMACEUTICAL CO., LTD. (JP) 2025-10-02 US disclosed
US-12391674-B2 Heterocyclic compounds for the treatment of epilepsy OTSUKA PHARMACEUTICAL CO., LTD. (JP) 2025-08-19 US disclosed
US-20210403456-A1 HETEROCYCLIC COMPOUNDS FOR THE TREATMENT OF EPILEPSY OTSUKA PHARMACEUTICAL CO., LTD. (JP) 2021-12-30 US disclosed
US-20210403456-A1 HETEROCYCLIC COMPOUNDS FOR THE TREATMENT OF EPILEPSY OTSUKA PHARMACEUTICAL CO., LTD. (JP) 2021-12-30 US disclosed
EP-3887358-A1 HETEROCYCLIC COMPOUNDS FOR THE TREATMENT OF EPILEPSY Otsuka Pharmaceutical Co., Ltd. (JP) 2021-10-06 EP disclosed
CN-113166076-A Heterocyclic compounds for the treatment of epilepsy 大塚制药株式会社 2021-07-23 CN disclosed
WO-2020111263-A1 HETEROCYCLIC COMPOUNDS FOR THE TREATMENT OF EPILEPSY OTSUKA PHARMACEUTICAL CO., LTD. (JP) 2020-06-04 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-12391674-B2 Heterocyclic compounds for the treatment of epilepsy SLC6A11, SCN1A, SCN1B MMP2 2858/4885MMP9 2168/4885MMP13 2824/4885
US-20210403456-A1 HETEROCYCLIC COMPOUNDS FOR THE TREATMENT OF EPILEPSY SLC6A11, SCN1A, SCN1B MMP2 2858/4885MMP9 2168/4885MMP13 2824/4885
US-20250304558-A1 HETEROCYCLIC COMPOUNDS FOR THE TREATMENT OF EPILEPSY SLC6A11, SCN1A, KCNH1 MMP2 2782/4885MMP9 2157/4885MMP13 2444/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.